COGT vs ALGS vs PRAX vs CRL

For growth investors, Charles River Laboratories International, Inc.

(CRL) is the stronger pick with -0. 9% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Analysts rate Cogent Biosciences, Inc. (COGT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cogent Biosciences, Inc.

(COGT) delivered a total return of +318. 7%, compared to -99. 1% for Aligos Therapeutics, Inc. (ALGS). Over 10 years, the gap is even starker: CRL returned +114. 0% versus ALGS's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Praxis Precision Medicines, Inc.

(PRAX) is the lower-risk stock at 1. 40β versus Aligos Therapeutics, Inc. 's 2. 08β — meaning ALGS is approximately 49% more volatile than PRAX relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Charles River Laboratories International, Inc.

(CRL) is pulling ahead at -0. 9% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Aligos Therapeutics, Inc. grew EPS 88. 3% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, CRL leads at 0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cogent Biosciences, Inc.

(COGT) is the more profitable company, earning 0. 0% net margin versus -1106. 7% for Aligos Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRL leads at 12. 6% versus -40. 2% for ALGS. At the gross margin level — before operating expenses — ALGS leads at 57. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRAX: 64.

7% to $548. 80.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Charles River Laboratories International, Inc.

(CRL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+114. 0% 10Y return). Aligos Therapeutics, Inc. (ALGS) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRL: +114. 0%, ALGS: -98. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.